Morningstar

Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule

This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression ...
UC San Francisco

Scientists May Have Found How to Diagnose Elusive Neuro Disorder

Progressive supranuclear palsy (PSP), a mysterious and deadly neurological disorder, usually goes undiagnosed until after a patient dies and an autopsy is performed. But now, UC San Francisco ...
아시아경제

GemVax Completes Patient Recruitment for Phase 2 Clinical Trial of Progressive Supranuclear Palsy

GemVax & Kael Kael announced on the 28th that it has completed patient recruitment for the domestic Phase 2 clinical trial of GV1001, a treatment for progressive supranuclear palsy (PSP). The Phase 2 ...
Business Wire

Alzprotect Announces Supportive Results from Open-Label Extension of Phase 2a Study for Progressive Supranuclear Palsy (PSP)

LILLE, France--(BUSINESS WIRE)--Alzprotect, a French biopharmaceutical company, is pleased to announce the successful completion of the open-label extension (OLE) phase following the Phase 2a clinical ...
Business Wire

Alzprotect Forges Ahead with First Patients Enrolled in Phase 2a Study in Progressive Supranuclear Palsy (PSP)

LILLE, France--(BUSINESS WIRE)--ALZPROTECT (http://www.alzprotect.com/en), a biopharmaceutical company developing treatments for Alzheimer’s disease, today ...